AR102149A1 - DIRECTED ANTIBODIES AGAINST TICAGRELOR AND METHODS FOR USE - Google Patents
DIRECTED ANTIBODIES AGAINST TICAGRELOR AND METHODS FOR USEInfo
- Publication number
- AR102149A1 AR102149A1 ARP150103174A ARP150103174A AR102149A1 AR 102149 A1 AR102149 A1 AR 102149A1 AR P150103174 A ARP150103174 A AR P150103174A AR P150103174 A ARP150103174 A AR P150103174A AR 102149 A1 AR102149 A1 AR 102149A1
- Authority
- AR
- Argentina
- Prior art keywords
- ticagrelor
- patient
- antibody
- group
- alkyl
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Un anticuerpo caracterizado porque se une específicamente a un compuesto de ciclopentiltriazolopirimidina de fórmula (1) en donde R¹ se selecciona del grupo que consiste en C₁₋₆ alcoxilo y C₁₋₆ alquiltio; R² se selecciona del grupo que consiste en H, C₁₋₆ alquilo, C₁₋₆ alquilo sustituido, C₃₋₆ cicloalquilo, y C₃₋₆ cicloalquilo sustituido; y R³ se selecciona del grupo que consiste en H, C₁₋₆ alquilo, C₁₋₆ alcoxilo, y C₁₋₆ alcanol. Reivindicación 41: Un método para tratar el sangrado agudo un paciente al que se ha administrado ticagrelor, caracterizado porque el método comprende administrar al paciente una cantidad eficaz del anticuerpo de cualquiera de las reivindicaciones 1 a 40. Reivindicación 42: Un método para tratar sangrado severo en un paciente que se ha sometido o que se está sometiendo a un procedimiento quirúrgico y al que se ha administrado ticagrelor, caracterizado porque el método comprende administrar al paciente una cantidad eficaz del anticuerpo de cualquiera de las reivindicaciones 1 a 40. Reivindicación 48: Una composición que comprende una molécula de ácido nucleico caracterizada porque comprende una secuencia que codifica para el anticuerpo de cualquiera de las reivindicaciones 22 a 26.Claim 1: An antibody characterized in that it specifically binds to a cyclopentyltriazolopyrimidine compound of formula (1) wherein R¹ is selected from the group consisting of C₁₋₆ alkoxy and C₁₋₆ alkylthio; R² is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ substituted alkyl, C₃₋₆ cycloalkyl, and C₃₋₆ substituted cycloalkyl; and R³ is selected from the group consisting of H, C₁₋₆ alkyl, C₁₋₆ alkoxy, and C₁₋₆ alkanol. Claim 41: A method for treating acute bleeding a patient to whom ticagrelor has been administered, characterized in that the method comprises administering to the patient an effective amount of the antibody of any of claims 1 to 40. Claim 42: A method for treating severe bleeding in a patient who has undergone or is undergoing a surgical procedure and to whom ticagrelor has been administered, characterized in that the method comprises administering to the patient an effective amount of the antibody of any of claims 1 to 40. Claim 48: A Composition comprising a nucleic acid molecule characterized in that it comprises a sequence encoding the antibody of any one of claims 22 to 26.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462058458P | 2014-10-01 | 2014-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102149A1 true AR102149A1 (en) | 2017-02-08 |
Family
ID=58698547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103174A AR102149A1 (en) | 2014-10-01 | 2015-10-01 | DIRECTED ANTIBODIES AGAINST TICAGRELOR AND METHODS FOR USE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR102149A1 (en) |
-
2015
- 2015-10-01 AR ARP150103174A patent/AR102149A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| EA201990495A1 (en) | BIARY COMPOUNDS APPLICABLE AS IMMUNOMODULATORS | |
| EA201691590A1 (en) | BENZIMIDAZOL-2-AMINES AS MIDHI INHIBITORS | |
| EA201991399A1 (en) | AMINOTRIAZOLOPYRIDINE COMPOUNDS AND THEIR APPLICATION IN TREATMENT OF CANCER | |
| EA201990221A1 (en) | 1,3-DIHYDROXIPHENYL DERIVATIVES APPLICABLE AS IMMUNOMODULATORS | |
| EA201692301A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EA201791018A1 (en) | DERIVATIVES OF 6-AMINO-7-BICYCLO-7-DEAZAPURIN AS PROTECTINININASE INHIBITORS | |
| EA201790195A1 (en) | METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS | |
| EA201792354A1 (en) | BATCHOLEIC ACID COMPOSITIONS AND METHODS OF APPLICATION | |
| EA201690406A1 (en) | GRP94 SELECTIVE INHIBITORS AND METHODS OF THEIR APPLICATION | |
| EA201691135A1 (en) | NEW GLUTAMINASE INHIBITORS | |
| EA201790078A1 (en) | MNK INHIBITORS AND RELATED METHODS | |
| EA201692506A2 (en) | ANTI-FLY VIRUS REPLICATION INHIBITORS | |
| EA201691988A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
| EA201791516A1 (en) | METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS | |
| EA201592068A1 (en) | INHANSER INHIBITORS ZESTE HOMOLOGIST 2 | |
| EA202191630A1 (en) | CHEMICALLY MODIFIED CONSTRUCTIONS FOR RNAi AND WAYS OF THEIR APPLICATION | |
| AR101740A1 (en) | COMBINATION AND COMPOSITION THERAPY | |
| EA201790576A1 (en) | Spirocyclic inhibitors of katepsin C | |
| EA201691881A1 (en) | NEW CONNECTIONS | |
| EA201692481A1 (en) | COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101 | |
| EA201592203A1 (en) | METHODS OF TREATMENT OF Taupathy | |
| EA201791907A1 (en) | BIVALENT VACCINE AGAINST SWINE FLU VIRUS | |
| EA201692470A1 (en) | PHARMACEUTICAL COMBINATIONS |